๐๐ฌ๐ข๐ฅ๐จ๐๐ฒ๐๐ข๐ง ๐ ๐จ๐ฎ๐ง๐ ๐๐จ ๐๐๐ฉ๐ข๐๐ฅ๐ฒ ๐๐ฆ๐ฉ๐ซ๐จ๐ฏ๐ ๐๐๐ฅ๐๐๐ก๐ฎ ๐๐ข๐ฅ๐ง๐ค๐ซ๐ ๐ฟ๐๐ฅ๐ง๐๐จ๐จ๐๐ซ๐ ๐๐ฎ๐ข๐ฅ๐ฉ๐ค๐ข๐จ ๐๐ฃ ๐๐๐ฉ๐๐๐ฃ๐ฉ๐จ ๐ฟ๐ช๐ง๐๐ฃ๐ โ๐๐ง๐ค๐ช๐ฃ๐๐๐ง๐๐๐ ๐๐ฃ๐โ ๐พ๐ก๐๐ฃ๐๐๐๐ก ๐๐ง๐๐๐ก
๐๐ฉ ๐ฉ๐ช๐ง๐ฃ๐จ ๐ค๐ช๐ฉ ๐ฉ๐๐๐ฉ ๐๐๐ซ๐๐ฃ๐ ๐ฅ๐จ๐๐ก๐ค๐๐ฎ๐๐๐ฃ, โฆ See more.
Compass Pathways, a U.K. based clinical stage company that is developing a patented form of psilocybin to be used in conjunction with therapy, reported promising results from its much-anticipated phase two b clinical trial this week. The study found that patients who took a single psychedelic dose of psilocybin, 25 milligrams, in conjunction with therapy reported almost immediate and significant reduction in depressive symptoms that lasted weeks compared with patients who were given a 1 milligram dose, which is so low itโs essentially a placebo.
Twenty-nine patients, or 36.7%, who took the 25 mg dose showed a 50% or more reduction in symptoms in three weeks after the single dose and again at three months, compared with the patients who took the placebo. Nineteen patients, or 24.1%, who took the highest dose were still in remission three months later, compared with 17.7% after three weeks and 10.1% after three months in the 1 mg group.
George Goldsmith, who cofounded Compass Pathways with his wife and medical doctor Ekaterina Malievskaia and Lars Christian Wilde, says that when they saw the positive results, they realized they were โgroundbreaking.โ